Results 241 to 250 of about 67,560 (281)
Some of the next articles are maybe not open access.
Phosphodiesterase type 5 inhibitors and kidney disease
International Urology and Nephrology, 2015Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar +6 more
openaire +2 more sources
Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?
European Urology, 2006To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data.Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to ...
MONTORSI , FRANCESCO +4 more
openaire +3 more sources
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Advances in Therapy, 2009Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role.
David, Montani +8 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviewse, 2011Abuse of sildenafil has been reported since its introduction in 1999 and commonly documented in combination with illicit drugs among men and women of all ages. Increased risks of sexually transmissible diseases including HIV have been associated with sildenafil use in men who have sex with men.
Gregory, Lowe, Raymond, Costabile
openaire +2 more sources
Nonurologic applications of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Phosphodiesterase type 5 (PDE5) is an enzyme that catalyzes hydrolytic degradation of cyclic guanosine monophosphate, an essential intracellular second messenger that modulates diverse biologic processes in living cells. Three selective inhibitors of PDE5, sildenafil, vardenafil, and tadalafil, have been successfully used by millions of people ...
Rakesh C. Kukreja +2 more
openaire +1 more source
Type 5 Phosphodiesterase Inhibitors: Curing Erectile Dysfunction
European Urology, 2006Basic science research on erectile physiology has focused on the pathogenesis of erectile dysfunction (ED) and has provided convincing evidence that ED is predominately a disease of vascular etiology correlating with coronary artery disease, hypertension, atherosclerosis, hyperlipidemia, smoking, and diabetes mellitus [1,2].
Wayne J.G. Hellstrom, Muammer Kendirci
openaire +1 more source
Phosphodiesterase type 5 inhibitors and endothelial function
Current Sexual Health Reports, 2007Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage.
Antonio Aversa, Roberto Bruzziches
openaire +1 more source
Current Pharmaceutical Design, 2005
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
N, Hosogai +12 more
openaire +2 more sources
Chronic dosing of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2008Ten years ago, the introduction of sildenafil citrate for the treatment of erectile dysfunction fundamentally changed the field of sexual medicine. The sexual indications, along with the pharmacologic characteristics of this drug, led to its approval for on-demand use.
openaire +1 more source